Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
104 Results for "
mononuclear cell
" in MedChemExpress (MCE) Product Catalog:
Products (104)
104 Results for "mononuclear cell" in MCE Product Catalog:
Cat. No.: HY-NP077A
Cat. No.: HY-103697R
CAS No.: 1020412-43-4
Research Areas:
Gardiquimod (Standard) is the analytical standard of Gardiquimod. This product is intended for research and analytical applications. Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM.
Cat. No.: HY-153952
CAS No.: 2757469-20-6
Research Areas:
Immuno modulator-1 (compound 22) inhibits TNFα and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC50 values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM .
Cat. No.: HY-149356
CAS No.: 3049472-36-5
Target:
Research Areas:
PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC50=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells .
Target:
Research Areas:
5J-4 is a potent CRAC inhibitor. 5J-4 decreases the numbers of infiltrated mononuclear cell into the CNS, and significantly decreases the population of infiltrated CD4+ population. 5J-4 reduces the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in mouse model of inflammation .
Cat. No.: HY-103697AR
CAS No.: 1159840-61-5
Research Areas:
Gardiquimod (diTFA) (Standard) is the analytical standard of Gardiquimod (diTFA). This product is intended for research and analytical applications. Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.
Category:
Alkaloids Monophenols Phenols Nymphaeaceae Extract Nelumbo nucifera Gaertn. Plants Other Families Extract Isoquinoline Alkaloids
Target:
Cat. No.: HY-N15307
CAS No.: 38070-97-2
Target:
Cat. No.: HY-B1899AR
CAS No.: 110026-03-4
Synonyms: Taurodeoxycholate sodium hydrate (Standard)
Category:
Cat. No.: HY-150749
CAS No.: 1198621-85-0
Target:
Research Areas:
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
Cat. No.: HY-118848
CAS No.: 111525-11-2
Target:
Research Areas:
A63162 is a specific 5-lipoxygenase (5-LOX) inhibitor. A63162 inhibits mitogen (PHA)-induced horse mononuclear cell (BMC) proliferation and inhibits Calcimycin (HY-N6687)-induced leukotriene LTB4 synthesis at the same concentration. A63162 can be used in the study of chronic obstructive pulmonary disease, arthritis and inflammatory bowel disease .
Cat. No.: HY-124954
CAS No.: 501926-82-5
Target:
Research Areas:
MN-25 (compound 4a) is an orally active indolpyridone that serves as a novel cannabinoid ligand. MN-25 has Ki of 245 nM and 11 nM for CB1 and CB2. MN-25 has CB2 agonist activity and inhibits TNF-R release in human peripheral blood mononuclear cells in vitro with an IC50 of 33 μM. MN-25 shows efficacy in a mouse acute inflammation model at oral doses up to 50 mg/kg >[1].
Cat. No.: HY-168074
Target:
Research Areas:
4″-C18 EGCG is a potent inhibitor of α-amylase and α-glucosidase with IC50 values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM .
Cat. No.: HY-122566
CAS No.: 903864-87-9
Synonyms: ZINC666243
Target:
Research Areas:
SMU127 is an agonist of the toll-like receptor 1/2 (TLR1/2) heterodimer. It induces NF-κB signaling in cells expressing human TLR2 (EC50=0.55 μM) but not cells expressing human TLR3, -4, -5, -7, or -8 when used at concentrations ranging from 0.1 to 100 μM. SMU127 induces the production of TNF-α in isolated human peripheral blood mononuclear cells (PBMCs) when used at concentrations ranging from 0.01 to 1 μM. In vivo, SMU127 (0.1 mg/animal) reduces tumor volume in a 4T1 murine mammary carcinoma model.
Cat. No.: HY-162819
Apoptosis inducer 26 (compound [AgCl(dap2SH)(PPh3)2]) is an autophagy inducer based on mononuclear Ag(I) ligands, with antibacterial and anticancer activities against a variety of bacterial strains and cancer cell lines. Apoptosis inducer 26 can effectively inhibit the growth of both Gram(+) and Gram(-) bacteria by causing the accumulation of Ag(I) ions in the bacterial periplasm. Apoptosis inducer 26 can intercalate between base pairs of CT DNA and induce apoptosis in A549 cells. Apoptosis inducer 26 also has the ability to scavenge free radicals, which can protect against oxidative stress .
Cat. No.: HY-168384
CAS No.: 875158-73-9
Target:
Research Areas:
M04 is an agonist of STING. It induces the expression of the IFN reporter gene in HEK293T cells expressing wild-type human STING, but does not induce this expression in HEK293T cells expressing the R71H-G230A-R293Q (HAQ) STING variant or in mouse RAW 264.7 cells, indicating that its activity is dependent on allelic and species variations. M04 induces the production of TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At a concentration of 50 µM, M04 stimulates dendritic cells isolated from PBMCs to express the MHC class II cell surface receptor HLA-DR and co-stimulatory molecules CD40, CD80, and CD86, and also enhances their ability to activate T cells in an ex vivo assay. M04 can be used in research on inflammatory immune diseases .
Cat. No.: HY-145473
CAS No.: 947381-58-0
Synonyms: 15(S)-HETE-SAPE; 15(S)-Hydroxyeicosatetraenoic acid-SAPE; 1-Stearoyl-2-15(S)-HETE-sn-glycero-3-Phosphatidylethanolamine
Target:
Research Areas:
1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE (15(S)-HETE-SAPE) is a phospholipid containing stearic acid (HY-B2219) at the sn-1 position and 15(S)-HETE (HY-113336) at the sn-2 position. 1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PE is formed by direct oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PE (SAPE) by 15-LOX in human peripheral mononuclear cells activated with the calcium ionophore A23187 (HY-N6687).
Cat. No.: HY-W587905
CAS No.: 145986-11-4
Target:
Research Areas:
Lamivudine impurity 9 is an L-oxathiolanyl nucleoside. Lamivudine impurity 9 exhibits anti-HIV-1 activity with EC50 > 100 μM in human peripheral blood mononuclear cells, and it shows no cytotoxicity even at concentrations up to 100 μM in human peripheral blood mononuclear cells and Vero cells .
Cat. No.: HY-112481
CAS No.: 354810-80-3
Research Areas:
IKK2-IN-5 is a selective IKK-2 inhibitor with an IC50 of 0.025 μM. IKK2-IN-5 inhibits the production of TNF-α in LPS (HY-D1056)-stimulated human peripheral blood mononuclear cells. IKK2-IN-5 exhibits extremely low cytotoxicity against human peripheral blood mononuclear cells .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
